




RealRate

PHARMACEUTICAL 2023

ImmunoGen Inc.
Rank 283 of 446

immu·gen





PHARMACEUTICAL 2023

ImmunoGen Inc.
Rank 283 of 446



The relative strengths and weaknesses of ImmunoGen Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ImmunoGen Inc. compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 17% points. The greatest weakness of ImmunoGen Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 28% points.

The company's Economic Capital Ratio, given in the ranking table, is 17%, being 27% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	304,121
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	121,858
Liabilities, Non-Current	47,803
Other Assets	40,438
Other Compr. Net Income	0
Other Expenses	5,559
Other Liabilities	23,449
Other Net Income	3,347
Other Revenues	108,782
Property and Equipment	4,377
Research and Development	213,370
Selling, General and Administrative Expense	116,129

Output Variable	Value in 1000 USD
Assets	348,936
Liabilities	193,110
Expenses	335,058
Revenues	108,782
Stockholders Equity	155,826
Net Income	-222,929
Comprehensive Net Income	-222,929
Economic Capital Ratio	17%